Quantum BioPharma Ltd (0K91G)

Frankfurt


	Symbol		Exchange		Currency
	QNTM		CSE		CAD	Delayed
	QNTM		NASDAQ		USD	Real-time
	QNTM		CBOE Canada		CAD	Real-time
	0K91G		Frankfurt		EUR	Delayed

Currency in EUR

3.1200

-0.0200(-0.64%)

Delayed Data02:10:07

Fair Value

Day's Range

3.1200

3.1200

52 wk Range

2.8000

62.4000

0K91G Income Statement

Explore the detailed Quantum BioPharma Ltd income statement, offering a comprehensive view of the company’s financial performance. Review essential metrics such as revenue, gross profit, operating income, and net income over selected periods. This page provides a clear breakdown of profitability and operational efficiency, helping you evaluate Quantum BioPharma Ltd's growth trends and overall financial health.

Advanced Income Statement

Period Ending:

2016

31/12

2017

31/12

2018

31/12

2019

31/12

2020

31/12

2021

31/12

2022

31/12

2023

31/12

Total Revenues

-

-

-

Total Revenues Growth

-

-

-

Cost Of Revenues

-

-

-

Gross Profit

-

-

-

Gross Profit Growth

-

-

-

Gross Profit Margin %

-

-

-

Other Operating Expenses, Total

33.74

27.43

19.23

	Other Operating Expenses, Total Growth
	R&D Expenses
	Selling General & Admin Expenses
	Other Operating Expenses

aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	+13.07%	-18.71%	-29.88%
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	6.33	6.91	3.86
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	23.37	15.98	12.87
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-	-	-

Operating Income

-33.74

-27.43

-19.23

Operating Income Growth

-13.07%

+18.71%

+29.88%

EBIT Margin %

-

-

-

Net Interest Expenses

-0.07

0.32

0.79

Net Interest Expenses Growth

+70.63%

+568.22%

+146.48%

Interest Expense, Total

-0.07

-0.05

-0

Interest And Investment Income

0

0.37

0.79

Other Non Operating Expenses, Total

0.68

0.52

0.21

EBT, Excl. Unusual Items

-33.13

-26.59

-18.24

Gain (Loss) On Sale Of Assets

-

-

-

Other Unusual Items, Total

0.05

0.12

0.38

EBT, Incl. Unusual Items

-33.94

-26.7

-18.23

EBT, Incl. Unusual Items Growth

-19.28%

+21.32%

+31.73%

EBT, Incl. Unusual Items Margin

-

-

-

Income Tax Expense

-

-

-

Net Income to Company

-35.29

-23.61

-18.23

Minority Interest

-

-

0.33

Net Income

-35.29

-23.61

-17.9

Net Income Growth

-10.96%

+33.1%

+24.17%

Net Income Margin %

-

-

-

Preferred Dividend and Other Adjustments

-

-

-

Net Income to Common Excl. Extra Items

-33.94

-26.7

-17.9

Basic EPS - Continuing Operations

-63.13

-44.81

-29.39

Basic EPS - Continuing Operations Growth

+58.89%

+29.01%

+34.41%

Diluted EPS - Continuing Operations

-63.13

-44.81

-29.39

Diluted EPS - Continuing Operations Growth

+58.89%

+29.01%

+34.41%

Basic Weighted Average Shares Outstanding

0.54

0.6

0.61

Diluted Weighted Average Shares Outstanding

0.54

0.6

0.61

Dividend Per Share

-

-

-

Dividend Per Share Growth

-

-

-

EBITDA

-29.7

-22.9

-16.73

EBITDA Growth

-14.47%

+22.91%

+26.94%

EBITDA Margin %

-

-

-

EBIT